UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 2, 2025

Date of Report (Date of Earliest Event Reported): August 6, 2025

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37625		46-3003182
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)


75 Hayden Avenue Lexington, Massachusetts	02421
Delaware	001-37625	46-3003182
(Address of principal executive offices)	(Zip Code)
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(I.R.S. EmployerIdentification No.)


75 Hayden AvenueLexington, Massachusetts		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (857) 259-5340

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~☐Written~~¨ Soliciting ~~communications~~material pursuant to Rule ~~425~~14a-12 under the ~~Securities~~Exchange Act (17 CFR ~~230~~240.~~425~~14a-12)

~~☐Soliciting~~¨ Pre-commencement ~~material~~communications pursuant to Rule ~~14a~~14d-12 2(b) under the Exchange Act (17 CFR 240.~~14a~~14d-122(b))

☐¨ Pre-commencement communications pursuant to Rule ~~14d~~13e-24(bc) under the Exchange Act (17 CFR 240.~~14d~~13e-24(bc))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	VYGR	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ¨

Item 7.01. Regulation FD Disclosure.

Voyager Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at Citi’s 2025 Biopharma Back to School Conference on September 2, 2025 at 4:00 p.m. ET.

A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Item 27.0201 and Exhibit 99.1) ~~Results~~shall not be deemed “filed” for purposes of ~~Operations~~Section ~~and~~18 ~~Financial~~of ~~Condition~~the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

OnBy ~~August~~providing 6the ~~2025,~~information ~~Voyager~~in ~~Therapeutics~~Item 7.01 of this Current Report on Form 8-K, ~~Inc~~including Exhibit 99.1 (hereto, the “Company”) ~~announced~~is ~~second~~not ~~quarter~~making ~~2025~~an ~~financial~~admission ~~results~~as ~~and~~to ~~corporate~~the ~~updates~~materiality of any information herein. The ~~full~~information ~~text~~contained ofin this Current Report on Form 8-K is intended to be considered in the ~~press~~context ~~release~~of ~~issued~~more complete information included in ~~connection~~the Company’s filings with the ~~announcement~~SEC isand ~~furnished~~other aspublic ~~Exhibit~~announcements 99that the Company has made and may make from time to time by press release or otherwise.1 The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, ~~and~~although it may do so from time to time as its management believes is ~~incorporated~~appropriate. byAny ~~reference~~such ~~herein~~updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description

99.1		Voyager Therapeutics, Inc. Presentation September 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:


ExhibitNo.		Description

99.1		Press release dated August 6, 2025 entitled “Voyager Reports Second Quarter 2025 Financial and Operating Results”.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 2, 2025	VOYAGER THERAPEUTICS, INC.

	By:	/s/ Nathan Jorgensen, Ph.D.
		Nathan Jorgensen, Ph.D.
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

ar
Date: August 6, 2025	VOYAGER THERAPEUTICS, INC.

	By:	/s/ Alfred Sandrock, M.D., Ph.D.
		Alfred Sandrock, M.D., Ph.D.
		Chief Executive Officer, President, and Director(Principal Executive Officer)

Filing Compare · Voyager Therapeutics, Inc.